Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Patient Satisfaction With Timolol Maleate in Sorbate, Generic Timolol Gel Forming Solution or Timolol Hemihydrate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

This study compares patient symptoms and anterior segment safety in patients treated with timolol hemihydrate, generic timolol gel forming solution or timolol maleate.

Inclusion Criteria:

• willing to comply with investigator's and protocol's instructions
• patients signature on the informed consent document
• primary open-angle glaucoma, pigment dispersion or exfoliation glaucoma, or ocular hypertension in at least one eye
• at screening intraocular pressure must be considered to be safe, in both eyes
• in non-qualifying eyes the intraocular pressure should be able to be controlled safely on no pharmacologic therapy or on study medicine alone
• currently treated with one glaucoma medication, untreated intraocular pressure of less than or equal to 28 mm Hg at visit 2 in both eyes

Exclusion Criteria:

• any abnormality preventing reliable applanation tonometry in either eye
• any opacity or subject uncooperativeness that restricts adequate examination of the ocular fundus or anterior chamber in either eye
• any concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye
• any history of allergic hypersensitivity or poor tolerance to any components of the preparations used in this trial
• females of childbearing potential not using reliable means of birth control
• pregnant or lactating females
• any clinically significant, serious, or severe medical or psychiatric condition
• participation (or current participation) in any investigational drug or device trial within 30 days prior to Visit 1
• severe prior visual acuity or field loss from any cause
• inability to understand the trial procedures, and thus inability to give informed consent
• progressive retinal or optic nerve disease apart from glaucoma
• serious systemic or ocular disease
• intraocular laser surgery within the past three months or corneal or intraocular conventional surgery within the past 6 months
• concurrent use of systemic corticosteroids, by IV, oral, dermal or topical ophthalmic route.
• subjects requiring tear replacement drops or allergy medications with sympathomimetics 24 hours prior to a scheduled study visit
• contraindication to beta-blocker usage including: reactive airway disease, uncontrolled heart failure, or second as well as third degree cardiac block, myasthenia gravis
• any subject the investigator believes will be at risk for glaucomatous progression by their participation in this trial